LUMOSA THERAPEUTICS CO (ROCO:6535) EV-to-Revenue : 557.58 (As of May. 25, 2024)

View and export this data going back to 2015. Start your Free Trial

What is LUMOSA THERAPEUTICS CO EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, LUMOSA THERAPEUTICS CO's enterprise value is NT$29,776.63 Mil. LUMOSA THERAPEUTICS CO's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was NT$53.40 Mil. Therefore, LUMOSA THERAPEUTICS CO's EV-to-Revenue for today is 557.58.

The historical rank and industry rank for LUMOSA THERAPEUTICS CO's EV-to-Revenue or its related term are showing as below:

ROCO:6535' s EV-to-Revenue Range Over the Past 10 Years
Min: 12.02 Med: 168.03 Max: 695.92
Current: 557.58

During the past 12 years, the highest EV-to-Revenue of LUMOSA THERAPEUTICS CO was 695.92. The lowest was 12.02. And the median was 168.03.

ROCO:6535's EV-to-Revenue is ranked worse than
92.88% of 1039 companies
in the Biotechnology industry
Industry Median: 8.18 vs ROCO:6535: 557.58

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-25), LUMOSA THERAPEUTICS CO's stock price is NT$184.50. LUMOSA THERAPEUTICS CO's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was NT$0.33. Therefore, LUMOSA THERAPEUTICS CO's PS Ratio for today is 562.50.

LUMOSA THERAPEUTICS CO EV-to-Revenue Historical Data

The historical data trend for LUMOSA THERAPEUTICS CO's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LUMOSA THERAPEUTICS CO EV-to-Revenue Chart

LUMOSA THERAPEUTICS CO Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

19.94

182.02

295.25

198.42

183.85

LUMOSA THERAPEUTICS CO Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															177.50	219.79	175.91	183.85	539.54

Competitive Comparison of LUMOSA THERAPEUTICS CO's EV-to-Revenue

For the Biotechnology subindustry, LUMOSA THERAPEUTICS CO's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LUMOSA THERAPEUTICS CO's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LUMOSA THERAPEUTICS CO's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where LUMOSA THERAPEUTICS CO's EV-to-Revenue falls into.

LUMOSA THERAPEUTICS CO EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

LUMOSA THERAPEUTICS CO's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	29776.625	/	53.403
	=	557.58

LUMOSA THERAPEUTICS CO's current Enterprise Value is NT$29,776.63 Mil.
LUMOSA THERAPEUTICS CO's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$53.40 Mil.

LUMOSA THERAPEUTICS CO (ROCO:6535) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

LUMOSA THERAPEUTICS CO's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	184.50	/	0.328
	=	562.50

LUMOSA THERAPEUTICS CO's share price for today is NT$184.50.
LUMOSA THERAPEUTICS CO's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.33.

LUMOSA THERAPEUTICS CO EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of LUMOSA THERAPEUTICS CO's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

LUMOSA THERAPEUTICS CO (ROCO:6535) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LUMOSA THERAPEUTICS CO LTD (ROCO:6535) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Yuanyuan Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503

Website

https://www.lumosa.com.tw

LUMOSA THERAPEUTICS CO LTD develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of CNS, oncology, and inflammatory diseases. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan and America. Its product portfolio includes LT - 1001 and LT - 3001 for Analgesic Injection and Novel Small Molecules for the Treatment of Acute Ischemic Stroke.

LUMOSA THERAPEUTICS CO (ROCO:6535) Headlines

No Headlines